AMOTL2
Angiomotin-like 2: A Scaffold Protein in Hippo Signaling and Cell Polarity
Gene Information Card
| Symbol | AMOTL2 |
|---|---|
| Full Name | Angiomotin like 2 |
| Gene Type | protein-coding |
| Chromosomal Location | 3q22.1 |
| NCBI Gene ID | 51421 ncbi.nlm.nih.gov/gene/51421 |
| Ensembl ID | ENSG00000114019 |
| UniProt ID | Q9Y2J4 |
| OMIM ID | 614769 |
| HGNC ID | 17812 |
| Aliases | JEAP, LCCP, MGC119027, MGC119028, MGC119029 |
Description
AMOTL2 encodes angiomotin-like 2, a member of the angiomotin family of scaffold proteins. It localizes to tight junctions and regulates cell polarity, migration, and proliferation by modulating the Hippo signaling pathway through interaction with YAP1 and WWTR1 (TAZ). AMOTL2 also influences angiogenesis and endothelial cell function.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Breast cancer | Dysregulation of AMOTL2 expression alters YAP/TAZ activity, promoting cell proliferation and invasion. | COSMIC; PMID: 25944712 |
| Colorectal cancer | Reduced AMOTL2 expression correlates with poor prognosis and increased YAP nuclear localization. | COSMIC; PMID: 28424480 |
| Hepatocellular carcinoma | AMOTL2 overexpression linked to tumor growth via Hippo pathway modulation. | COSMIC; PMID: 29395075 |
| Gastric cancer | AMOTL2 downregulation associated with metastasis and worse survival. | COSMIC; PMID: 27323851 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Heart | 12.8 | Medium |
| Lung | 8.5 | Low |
| Liver | 6.2 | Low |
| Kidney | 10.1 | Medium |
| Breast | 7.3 | Low |
| Colon | 9.4 | Medium |
| Brain | 5.6 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| MCF7 (breast cancer) | 11.2 | Moderate expression |
| HCT116 (colorectal cancer) | 14.5 | High expression |
| HepG2 (liver cancer) | 9.8 | Moderate expression |
| A549 (lung cancer) | 7.1 | Low expression |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| p.R81W | Missense | <0.1% | Unknown functional impact; reported in COSMIC |
| p.E123K | Missense | <0.1% | Located in coiled-coil domain; potential effect on protein interactions |
| p.S287L | Missense | <0.1% | Reported in breast cancer; functional significance unclear |
Mutation functional classification
Loss of Function (LOF)
No confirmed loss-of-function mutations reported in major databases.
Gain of Function (GOF)
No confirmed gain-of-function mutations reported.
Dominant Negative (DN)
No confirmed dominant-negative mutations reported.
View complete mutation data：
Gene Ontology (GO)
| • protein binding (GO:0005515) | • cell-cell adherens junction (GO:0005913) |
| • bicellular tight junction (GO:0005923) | • lateral plasma membrane (GO:0016328) |
| • hippo signaling (GO:0035329) | • cell-cell junction organization (GO:0045216) |
| • canonical Wnt signaling pathway (GO:0060070) | • cell-cell adhesion (GO:0098609) |
Pathways
• Hippo signaling pathway (Reactome: R-HSA-2028269)
• Tight junction interactions (Reactome: R-HSA-420029)
• YAP/TAZ regulation (Reactome: R-HSA-8939211)
Protein Summary
AMOTL2 is a 796-amino-acid protein containing coiled-coil domains and a C-terminal PDZ-binding motif. It localizes to tight junctions and interacts with YAP1 and TAZ to inhibit their nuclear translocation, thereby suppressing Hippo target gene transcription. AMOTL2 also binds actin and regulates cytoskeletal dynamics, cell migration, and angiogenesis.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| AMOTL2 Knockout HEK293 Cell Line | EDJ-KQ11090 | Human | 51421 | Details Get a Quote |
| AMOTL2 Knockout A-549 Cell Line | EDJ-KQ39030 | Human | 51421 | Details Get a Quote |
| AMOTL2 Knockout HCT 116 Cell Line | EDJ-KQ39031 | Human | 51421 | Details Get a Quote |
| AMOTL2 Knockout HeLa Cell Line | EDJ-KQ39032 | Human | 51421 | Details Get a Quote |
